Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China

Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)

Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders

Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise

Bristol Myers Squibb and Bain Capital launch biotech company NewCo

NewCo’s pipeline includes five investigational medicines

GSK forges $12 billion alliance with Hengrui Pharma

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

Milestone Pharmaceuticals announces FDA acceptance of response to Cardamyst nasal spray CRL

Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments

Sun Pharma settles patent litigation with Incyte

FDA approves Bravecto Quantum from Merck Animal Health

AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research

The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing

Amyris expands precision fermentation line in Brazil

Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M

Pfizer inks $1.25 billion cancer antibody licensing deal with China's 3SBio

3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion